Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Myeloproliferative Neoplasms
•
Hematology
What aspirin dose do you favor for thrombotic prophylaxis in myeloproliferative neoplasms?
81 mg vs 162 mg
Answer from: at Academic Institution
I generally use 81 mg twice a day. If they have had a thrombotic event, or have microvascular symptoms, then I use 81 mg BiD.
Sign in or Register to read more
14664
Related Questions
What experience have you had with familial clustering of polycythemia vera?
How do you decide between using ropeginterferon alfa-2b and peginterferon alfa-2a in MPN?
For patients with essential thrombocythemia already on prophylactic dose DOACs, do you defer starting aspirin?
In which patients with essential thrombocythemia would you use ropeginterferon alfa-2b?
How does triple-negative status influence your management of ET?
Would you change therapy for a CML patient in hematologic remission on imatinib found with positive qualitative BCR-ABL1 for the p230 protein?
Under which circumstances would you prefer ropeginterferon over hydroxyurea for patients with Polycythemia Vera?
For patients with intermediate or lower risk essential thrombocythemia with plt >1000 but no symptoms, do you favor aspirin only therapy or aspirin and cytoreduction?
Does tolerance of prior BTKi therapy or specific agent used (e.g., ibrutinib, acalabrutinib) influence your starting dose of pirtobrutinib?
How do you monitor multiple myeloma in patients receiving dialysis?